Press Release and presentation

August 10, 2026 BSE Limited, National Stock Exchange of India Limited, Floor 25, P. J. Towers Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort Bandra (E), Mumbai - 400 001 Mumbai - 400051 Scrip Code: 530019 Symbol: JUBLPHARMA Sub: Press Release alongwith Earnings Presentation on the financials and operational performance of the Company for the quarter ended June 30, 2026 Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Dear Sirs, Pursuant to Provisions of Regulation 30 of the Listing Regulations, please find enclosed herewith the Press Release, Presentation and FAQs on the financials and performance of the Company for the quarter ended June 30, 2026. The above - mentioned documents would be simultaneously posted on the Company's website at www.jubilantpharmova.com. You are requested to kindly take the same on record. Thanking you, Yours faithfully, For Jubilant Pharmova Limited Naresh Kapoor Company Secretary Encl: as above Jubilant Pharmova Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 www.jubilantpharmova.com PRESS RELEASE Noida, Aug 10, 2026 J P – Q1’FY27 UBILANT HARMOVA RESULTS On track towards Vision 2030 Solid Revenue growth across all business segments continues Particulars (Rs. Cr.) Q1’FY26 Q4’FY26 Q1’FY27 Y-o-Y Revenue 1,901 2,290 2,229 17% Total Income 1,913 2,314 2,249 18% EBITDA 302 363 268 (11%) EBITDA Margin (%) 15.8% 15.7% 11.9% (385) bps Reported PAT 103 119 56 (45%) Reported PAT Margin 5.4% 5.2% 2.5% (285) bps The Board of Jubilant Pharmova Limited met today to approve financial results for the quarter ended June 30, 2026. Commenting on the Company’s performance for Q1’FY27, Mr. Shyam S Bhartia, Chairman Jubilant Pharmova Limited and Mr. Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova Limited said, “We are pleased to announce revenue of Rs. 2,229 Cr. for Q1’FY27, which reflects a solid growth of 17% on YoY basis. Revenue growth is broad based across all our business segments, but particularly strong in CDMO Sterile Injectables on the back of technology transfer revenues from the new & third line. EBITDA for the quarter stands at Rs. 268 Cr. EBITDA margins declined year-on-year, primarily due to the unavailability of high-margin SPECT radiopharmaceutical products in the Radiopharmaceuticals business. Additionally, margins were impacted by negligible third-party revenues and higher operating expenses, including incremental remediation costs at the CMO Montreal facility. Reported PAT for the period stands at Rs. 56 Cr. PAT margins decreased due to lower operating profitability and increase in depreciation. During Q1’FY27, post successful media-fills, Commercial batch production for SPECT radiopharmaceuticals has started and these batches are expected to be released in Q2’FY27. By H2’FY27, all the SPECT Radiopharmaceutical products are expected to be available. Therefore, we anticipate EBITDA margins to start to expand from H2’FY27 onwards. During Q1’FY27, we saw continued growth momentum in the Ruby-Fill® installs. In the Allergy Immunotherapy business, we witnessed increase in demand from both markets, US and Outside US. In the CDMO Sterile Injectables business, we saw incremental revenues from technology transfer programs, at Line 3 in Spokane. In the CRDMO business, we are witnessing increase in revenues from Biotech customer segment and custom manufacturing. In the Generics Business, we launched two new products. Lastly, in our Proprietary Novel drugs business, we continue to make progress in JBI-802 and JBI-778 clinical trials.” Segmental Business Performance Radiopharma - Leading Radiopharmaceutical manufacturer & 2nd largest Radiopharmacy network in the US Radiopharmaceuticals Q1’FY27 revenue grew by 19% to Rs. 322 Cr. and EBITDA for the period stood at Rs. 110 Cr. EBITDA margins decreased YoY due to unavailability of certain SPECT products. At CMO Montreal, Post Successful media-fills, Commercial batch production for SPECT radiopharmaceuticals has started and the batches will be released in Q2’FY27. By H2’FY27, all the SPECT Radiopharmaceutical products are expected to be available. In the Ruby-Fill®, as we can demonstrate superior value proposition against competition, we continue to attract new channel partners. Our Ruby-Fill® install base has grown by 26% in Q1’FY27 on an annualised basis. This improved scale is also helping to increase EBITDA margins in this product category. We are on track to introduce multiple new products in the PET and SPECT imaging from FY28 to FY29. The dosing for Phase 2 clinical trial for MIBG is complete and we expect to do NDA filing by H2’FY27. Radiopharmacy Q1’FY27 revenue grew by 17% YoY to Rs. 700 Cr. on the back of increase in volume from certain PET products. EBITDA for the period grew by 19% to Rs. 12 Cr. We continue to see high competitive intensity in the SPECT Radiopharmacy segment. On the other hand, we continue to see revenue growth and strong EBITDA margins in our PET manufacturing facilities (3 sites). The proposed investment of US$ 60+ million in six (6) new PET manufacturing network is underway. The new PET manufacturing sites will become operational in FY28. This investment will take the overall PET radiopharmacy network to Nine (9) sites, thereby strongly positioning Jubilant Pharmova’s radiopharmacy network as the second largest in the US and shall drive the future business growth & profitability. Allergy Immunotherapy - No. 2 in the US Sub-Cutaneous allergy immunotherapy market As the sole supplier of Venom in the US, we are expanding the overall market by increasing customer awareness. In the US Allergenic extracts, we are working to increase revenues. We are also working to increase the penetration in the markets outside the US. In Q1’FY27, revenues grew by 18% to Rs. 214 Cr., driven by strong growth in the US & outside US markets. EBITDA grew by 5% to Rs. 66 Cr. EBITDA margins reduced YoY due to lower production. CDMO Sterile Injectables – Leading contract manufacturer in North America, serving top global innovators Q1’FY27 revenue grew by 34% to Rs. 496 Cr. due to incremental revenue from Line 3. EBITDA for the period stood at Rs. 45 Cr. EBITDA margins were lower YoY due to negligible third-party revenues & higher operating expenses including incremental remediation cost at Montreal facility. At the Spokane facility, the capacity expansion program remains on track. Following the launch of our third Sterile Fill & Finish line (Line 3) in Q2’FY26, we are successfully ramping up revenues from technology transfer programs. Currently, 10+ products across multiple formats and vial sizes are undergoing technology transfer on Line 3. We also onboarded one of the world’s largest oncology products on Line 3. Commercial batch production is expected to commence in late FY27, subject to FDA approval of these products. Revenue at Spokane grew by 43% to Rs. 494 Cr. and EBITDA grew by 49% to Rs. 117 Cr. EBITDA margins also expanded by 100 basis points to 24%. Considering the new tariffs imposed by the US Government, large innovator pharmaceutical companies are increasingly seeking high-quality, US-based manufacturing, specifically, those with significant capacities with isolator technology. As a result, we are seeing strong traction in Requests for Proposals (RFPs) for the new lines. We are happy to share the completion of installation of Line 4. Post media-fills, Line 4 is expected to start generating technology transfer revenues in Q4’FY27. At Montreal facility, In Q1’FY27, we progressed to stabilize production for Radiopharmaceutical products. We also expect the operating losses to reduce from H2’FY27 due to increase in sales of SPECT Radiopharmaceutical products. Post the receipt of warning letter in Q1’FY27, we have responded to the FDA and apprised them on our remediation actions. In the medium term, we anticipate that the new isolator-based fill-and-finish [Showing first 8,000 characters — download PDF for full document]